How well do clinicians and patients agree on depression treatment outcomes? Implications for personalized medicine

Human Psychopharmacology

Volumn 29, Issue 6, 2014, Pages 528-536

  Dunlop, Boadie W ^a   McCabe, Bhrett ^b   Eudicone, James M ^b   Sheehan, John J ^c   Baker, Ross A ^d  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b BRISTOL MYERS SQUIBB   (United States)

^c ASTRAZENECA   (United Kingdom)

^d OTSUKA PHARMACEUTICAL DEVELOPMENT AND COMMERCIALIZATION INC   (United States)

Author keywords

antidepressants; clinical trials; outcomes assessment; patient reported outcome; personalized medicine; ratings

Indexed keywords

ANTIDEPRESSANT AGENT; ARIPIPRAZOLE; PIPERAZINE DERIVATIVE; QUINOLONE DERIVATIVE;

ADULT; ANXIETY; DEPRESSIVE DISORDER, MAJOR; FEMALE; HUMAN; MALE; MIDDLE AGED; PATHOPHYSIOLOGY; PERSONALIZED MEDICINE; PROCEDURES; PROGNOSIS; PSYCHOLOGICAL RATING SCALE; PSYCHOLOGY; RANDOMIZED CONTROLLED TRIAL (TOPIC); SELF REPORT; TREATMENT OUTCOME;

ADULT; ANTIDEPRESSIVE AGENTS; ANXIETY; DEPRESSIVE DISORDER, MAJOR; FEMALE; HUMANS; INDIVIDUALIZED MEDICINE; MALE; MIDDLE AGED; PIPERAZINES; PROGNOSIS; PSYCHIATRIC STATUS RATING SCALES; QUINOLONES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SELF REPORT; TREATMENT OUTCOME;

EID: 84912070745     PISSN: 08856222     EISSN: 10991077     Source Type: Journal    
DOI: 10.1002/hup.2428     Document Type: Article

References (36)

1. Beck AT, Steer RA, Brown GK,. 1996. Beck Depression Inventory: Second Edition Manual. The Psychological Corporation: San Antonio (TX).
2. Berman R, Fava M, Thase M, et al., 2009. Aripiprazole augmentation in major depression: a double-blind, placebo-controlled study in patients with inadequate response to antidepressants. CNS Spect 14: 197-206.
3. Berman RM, Marcus RN, Swanink R, et al., 2007. The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled study. J Clin Psychiatry 68: 843-853.
4. Bernstein IH, Rush AJ, Carmody TJ, et al., 2007. Clinical vs. self-report versions of the Quick Inventory of Depressive Symptomatology in a public sector sample. J Psychiatr Res 41: 239-246.
5. Corruble E, Legrand JM, Zvenigorowski H, Duret C, Guelfi JD,. 1999. Concordance between self-report and clinician's assessment of depression. J Psychiatr Res 33: 457-465.
6. Domken M, Scott J, Kelly P,. 1994. What factors predict discrepancies between self and observer ratings of depression? J Affect Disord 31: 253-259.
7. Dorz S, Borgherini G, Conforti D, Scarso C, Magni G,. 2004. Comparison of self-rated and clinician-rated measures of depressive symptoms: a naturalistic study. Psychol Psychother Theory Res Pract 77: 353-361.
8. Dunlop BW, Li T, Kornstein SG, et al., 2011a. Concordance between clinician and patient ratings as predictors of response, remission, and recurrence in major depressive disorder. J Psychiatr Res 45: 96-103.
9. Dunlop BW, Reddy S, Yang L, Lubaczewski S, Focht K, Gucio-Pabia CJ,. 2011b. Symptomatic and functional improvement in employed depressed patients: a double-blind clinical trial of desvenlafaxine versus placebo. J Clin Psychopharmacol 31: 569-576.
10. Dunlop BW, Binder EB, Cubells JF, et al., 2012a. Predictors of remission in depression to individual and combined treatments (PReDICT): study protocol for a randomized controlled trial. Trials 13: 106.
11. Dunlop BW, Li T, Kornstein SG, et al., 2010. Correlation between patient and clinician assessments of depression severity in the PREVENT study. Psychiatry Res 177: 177-183.
12. Dunlop BW, Thase M, Wun C, et al., 2012b. A meta-analysis of factors impacting detection of antidepressant efficacy in clinical trials: the importance of academic sites. Neuropsychopharmacology 37: 2830-2836.
13. Fava M, Rush AJ, Alpert JE, et al., 2006. What clinical and symptom features and comorbid disorders characterize outpatients with anxious major depressive disorder: a replication and extension. Can J Psychiatry 51: 823-835.
14. Frank E, Prien RF, Jarrett RB, et al., 1991. Conceptualization and rationale for consensus definitions of terms in major depressive disorder: remission, recovery, relapse, and recurrence. Arch Gen Psychiatry 48: 851-855.
15. Hamilton M,. A Rating Scale for Depression. 1960. J Neurol Neurosurg Psychiatry 23: 56-62.
16. Harding KJ, Rush AJ, Arbuckle M, et al., 2011. Measurement-based care in psychiatric practice: a policy framework for implementation. J Clin Psychiatry 72: 1136-1143.
17. Kroenke K, Spitzer RL, Williams JB,. 2001. The PHQ-9: validity of a brief depression severity measure. J Gen Int Med 16: 606-613.
18. Landin R, DeBrota D, DeVries T, Potter WZ, Demitrack MA,. 2000. The impact of restrictive entry criterion during the placebo lead-in period. Biometrics 56: 271-278.
19. Lewis A,. 1934. Melancholia: a clinical survey of depressive states. J Ment Sci 80: 1-42.
20. Marcus RN, McQuade RD, Carson WH, et al., 2008. The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a second multicenter, randomized, double-blind, placebo-controlled study. J Clin Psychopharmacol 28: 156-165.
21. Montgomery SA, Asberg M,. 1979. A new depression scale designed to be sensitive to change. Br J Psychiatry 134: 382-389.
22. Morris DW, Trivedi MH,. 2011. Measurement-based care for unipolar depression. Curr Psychiatry Rep 13: 446-458.
23. Rush AJ, Bernstein IH, Trivedi MH, et al., 2006a. An evaluation of the Quick Inventory of Depressive Symptomatology and the Rating Scale for Depression: A Sequenced Treatment Alternatives to Relieve Depression Trial report. Biol Psychiatry 59: 493-501.
24. Rush AJ, Carmody TJ, Ibrahim HM, et al., 2006b. Comparison of self-report and clinician ratings on two inventories of depressive symptomatology. Psychiatr Serv 57: 829-837.
25. Rush AJ, Gullion CM, Basco MR, Jarrett RB, Trivedi MH,. 1996. The Inventory of Depressive Symptomatology (IDS): psychometric properties. Psychol Med 26: 477-486.
26. Rush AJ, Trivedi MH, Carmody TJ, et al., 2005. Self-reported depressive symptom measures: sensitivity to detecting change in a randomized, controlled trial of chronically depressed, nonpsychotic outpatients. Neuropsychopharmacology 30: 405-416.
27. Rush A, Trivedi M, Ibrahim HM, et al., 2003. The 16-item Quick Inventory of Depressive Symptomatology (QIDS), Clinician rating (QIDS-C) and Self-Report (QIDS-SR16): a psychometric evaluation in patients with chronic major depression. Biol Psychiatry 56: 573-583.
28. Shankman SA, Klein DN,. 2003. The relation between depression and anxiety: an evaluation of the tripartite, approach-withdrawal and valence-arousal models. Clin Psychol Rev 23: 605-637.
29. Simon GE, Perlis RH,. 2010. Personalized medicine for depression: can we match patients with treatments? Am J Psychiatry 167: 1445-1455.
30. Smaar KL, Keefer AL,. 2011. Measures of depression and depressive symptoms. Arthritis Care Res 63 (Suppl 11): S454-466.
31. Trivedi MH, Rush AJ, Wisniewski SR, et al., 2006. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR∗D: implications for clinical practice. Am J Psychiatry 163: 28-40.
32. Zigmond AS, Snaith RP,. 1983. The Hospital Anxiety and Depression Scale. Acta Psychiatr Scand 67: 361-370.
33. Zimmerman M, Martinez JA, Attiullah N, et al., 2012a. Why do some depressed outpatients who are in remission according to the Hamilton Depression Rating Scale not consider themselves to be in remission? J Clin Psychiatry 73: 790-795.
34. Zimmerman M, Martinez JA, Friedman M, Boerescu DA, Attiullah N, Toba C,. 2012b. How can we use depression severity to guide treatment selection when measures of depression categorize patients differently? J Clin Psychiatry 73: 1287-1291.
35. Zimmerman M, Chelminski I, McGlinchey JB, Posternak MA,. 2008. A clinically useful depression outcomes scale. Compr Psychiatry 49: 131-140.
36. Zung WW,. 1965. A self-rating depression scale. Arch Gen Psychiatry 12: 63-70.